Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,518 questions in 135 reviews · Infectious Diseases
current versionsNo studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
A single dose of deworming drugs vs placebo Physical fitness · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 3 studies · 280 participants | Very low |
A single dose of deworming drugs vs placebo School attendance · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 1 study · 304 participants | Low |
A single dose of deworming drugs vs placebo School performance · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 1 study · 304 participants | Low |
A single dose of deworming drugs vs placebo Mortality · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Multiple doses of deworming drugs vs placebo Height (cm) · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 13 studies · 13700 participants | Moderate |
Multiple doses of deworming drugs vs placebo Haemoglobin (g/dL) · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 9 studies · 5498 participants | Moderate |
Multiple doses of deworming drugs vs placebo Formal tests of cognition · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 8 studies · 35394 participants | Moderate |
Multiple doses of deworming drugs vs placebo Physical fitness ‐ not measured · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Multiple doses of deworming drugs vs placebo School attendance · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 3 studies · 20650 participants | Very low |
Multiple doses of deworming drugs vs placebo School performance · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 4 studies · 34967 participants | Moderate |
Multiple doses of deworming drugs vs placebo Mortality (between ages 1 and 6 years) · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | RR 0.95 [0.89, 1.92] | 3 studies · 1005135 participants | Low |
A single dose of deworming drugs vs placebo Weight (kg) · public health programmes to regularly treat all children aged 16 years or less Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas (2019) · Cochrane | no estimate extracted | 14 studies · 4970 participants | Very low |
Intervention NR Microfilaraemia (mf) prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.95 [0.85, 1.07] | 12 studies · 5027 participants | High |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 2 studies · 169 participants | Very low |
Intervention NR Antigenaemia prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.07 [0.91, 1.25] | 2 studies · 1054 participants | High |
Intervention NR Antigen density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 2 studies · 371 participants | Very low |
Intervention NR Adult worm prevalence detected by ultrasound ‐ not measured · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.95 [0.61, 1.48] | 2 studies · 678 participants | Moderate |
Intervention NR Microfilaraemia (mf) prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.9 [0.75, 1.09] | 7 studies · 1102 participants | Moderate |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 6 studies · 559 participants | Very low |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 6 studies · 535 participants | Low |
Intervention NR Antigenaemia prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.03 [0.92, 1.14] | 5 studies · 954 participants | High |
Intervention NR Antigen density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 3 studies · 270 participants | Very low |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 10 studies · 1216 participants | Very low |
Intervention NR Adult worm prevalence detected by ultrasound · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.16 [0.72, 1.86] | 3 studies · 165 participants | Low |
Intervention NR Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.94 [0.79, 1.11] | 4 studies · 1589 participants | High |
Intervention NR Microfilaraemia (mf) prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.84 [0.54, 1.31] | 4 studies · 2519 participants | Moderate |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 3 studies · 372 participants | Very low |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 2 studies · 348 participants | Low |
Intervention NR Antigenaemia prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.04 [0.94, 1.16] | 2 studies · 1766 participants | High |
Intervention NR Antigen density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 2 studies · 733 participants | Low |
Intervention NR Adult worm prevalence detected by ultrasound ‐ not measured · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.16 [0.77, 1.74] | 1 study · 627 participants | Moderate |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 9 studies · 1052 participants | Very low |
Intervention NR Antigenaemia prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.04 [0.97, 1.12] | 7 studies · 3774 participants | High |
Intervention NR Antigen density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 5 studies · 1374 participants | Very low |
Intervention NR Adult worm prevalence detected by ultrasound · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 1.16 [0.72, 1.86] | 3 studies · 165 participants | Low |
Intervention NR Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.97 [0.84, 1.13] | 6 studies · 2894 participants | High |
Intervention NR Microfilaraemia (mf) prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | RR 0.98 [0.81, 1.19] | 4 studies · 1406 participants | High |
Intervention NR Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (2019) · Cochrane | no estimate extracted | 4 studies · 285 participants | Very low |
Intervention NR Clinical failure · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | RR 0.17 [0.02, 1.3] | 2 studies · 285 participants | Low |
Intervention NR Parasitological failure Method: stool microscopy demonstrating E histolytica cysts or trophozoites · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | RR 1.01 [0.58, 1.74] | 2 studies · 285 participants | Low |
Intervention NR Adverse events · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | RR 0.65 [0.46, 0.92] | 8 studies · 477 participants | Moderate |
Intervention NR Clinical failure 1 to 14 days after end of treatment · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | RR 0.33 [0.11, 0.98] | 3 studies · 1025 participants | Very low |
Intervention NR Parasitological failure 1 to 14 days after end of treatment Method: stool microscopy demonstrating E histolytica cysts or trophozoites · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | RR 0.36 [0.15, 0.86] | 3 studies · 720 participants | Low |
Intervention NR Adverse events · adults and children with amoebic colitis Antiamoebic drugs for treating amoebic colitis (2019) · Cochrane | no estimate extracted | 3 studies · 1025 participants | Very low |
Intervention NR Failure of rehydration · acute diarrhoea in children Racecadotril for acute diarrhoea in children (2019) · Cochrane | RR 0.41 [0.13, 1.23] | 2 studies · 192 participants | Low |
Intervention NR Duration of diarrhoea · acute diarrhoea in children Racecadotril for acute diarrhoea in children (2019) · Cochrane | no estimate extracted | 5 studies · 867 participants | Very low |
Intervention NR Number of stools: measured in the first 24 hours after introduction of racecadotril · acute diarrhoea in children Racecadotril for acute diarrhoea in children (2019) · Cochrane | no estimate extracted | 2 studies · 258 participants | Very low |
Intervention NR Stool output: measured in the first 48 hours after introduction of racecadotril · acute diarrhoea in children Racecadotril for acute diarrhoea in children (2019) · Cochrane | no estimate extracted | 2 studies · 301 participants | Low |